SUBSCRIBE TO TMCnet
TMCnet - World's Largest Communications and Technology Community

TMCNet:  Research and Markets: PharmaPoint: Meningococcal Vaccines - Global Drug Forecast and Market Analysis to 2022: Event-Driven Update

[March 12, 2014]

Research and Markets: PharmaPoint: Meningococcal Vaccines - Global Drug Forecast and Market Analysis to 2022: Event-Driven Update

DUBLIN --(Business Wire)--

Research and Markets (http://www.researchandmarkets.com/research/clcw7s/pharmapoint) has announced the addition of the "PharmaPoint: Meningococcal Vaccines - Global Drug Forecast and Market Analysis to 2022: Event-Driven Update" report to their offering.

New Serogroup B Vaccines to Claim Half of Meningococcal Vaccines Market by 2022

Upcoming and long-awaited market entries for Novartis' Bexsero and Pfizer's MnB rLP2086 will prompt significant growth in the meningococcal vaccines market over the next decade, states research and consulting firm The authors.

According to the report, the arrival of these eagerly awaited serogroup B vaccines will drive combined revenue for meningococcal vaccines across the US, France, Germany, Italy, Spain, the UK, Japan, Australia, and Brazil, from $1.2bn in 2012 to just over $2bn in 2022, increasing by 65%.

Novartis' Bexsero, which received approval from the European Medicines Agency (EMA (News - Alert)) in January, is forecast to produce global sales of over $330m by 2022, while Pfizer's MnB rLP2086, which is expected to launch in the U in 2017 and in the EU the following year, is forecast to reach total revenue of over $700m by 2022. Combined, these two products are expected to dominate the meningococcal vaccines market by the end of the forecast period, accounting for a 52% share.


According to Dr. Christopher Pace, The authors's analyst covering infectious disease: Despite legitimate concerns from policymakers regarding the cost-effectiveness of adding an additional vaccine to already-crowded immunization schedules, serogroup B incorporation will be well received by prescribers and patients, alike.

Novartis and Pfizer are expected to dominate this segment of the market, with their respective products responsible for the majority of global market growth over the next decade.

The authors's report states that the cost-effectiveness of meningococcal vaccines is a universal barrier to global market growth, with the inherently high cost per dose and relatively low incidence rates of meningococcal disease leading to increased government skepticism in the face of new vaccine launches and immunization program expansions.

Dr. Pace believes that while these concerns are not expected to significantly prohibit the adoption of serogroup B vaccines, such as Bexsero and MnB rLP2086, government assessment of cost-effectiveness is considered to be a primary determinant of a vaccine's commercial success.

Key Topics Covered

  1. Table of Contents
  2. Introduction
  3. Disease Overview
  4. Epidemiology
  5. Disease Management
  6. Competitive Assessment
  7. Opportunity and Unmet Need
  8. Pipeline Assessment
  9. Current and Future Players
  10. Market Outlook
  11. Appendix

Companies Mentioned

  • Baxter
  • GlaxoSmithKline
  • Novartis
  • Nuron Biotech
  • Pfizer
  • Sanofi

For more information visit http://www.researchandmarkets.com/research/clcw7s/pharmapoint

About Research and Markets

Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.


[ Back To Technology News's Homepage ]

OTHER NEWS PROVIDERS







Technology Marketing Corporation

800 Connecticut Ave, 1st Floor East, Norwalk, CT 06854 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments: tmc@tmcnet.com.
Comments about this site: webmaster@tmcnet.com.

STAY CURRENT YOUR WAY

© 2014 Technology Marketing Corporation. All rights reserved.